LCN2 and type 2 diabetes mellitus: In SAFE-PCI trial, we evaluated if SGLT2i (empagliflozin) prevents CI-AKI among T2D patients undergoing elective PCI, as expressed by blood levels of biomarkers NGAL and creatinine.